Ning et al. developed CD133Ab-NPs-SN-38 nanoparticles, which combine the anti-CD133 mAb and SN-38, an inhibitor of topoisomerase I. Compared with free SN-38 and nanoparticles loaded with SN-38 (NPs-SN-38), CD133Ab-NPs-SN-38 showed greater antitumor ability and precisely targeted and killed colorectal CSCs, inhibited tumor growth and delayed tumor recurrence, demonstrating that CD133 is a promising ADC target for colorectal CSC elimination [222]. Here, PROM1 is linked to neoplasm.